Hypera S.A.
Research Hypera S.A. (HM6A) on Bullrun: valuation model: 42.1% undervalued, market cap EUR 2.55B, P/E 8.2, dividend yield 5.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHM6A
- ExchangeF
- CountryBrazil
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Valuation signal42.1% undervalued
- Market capEUR 2.55B
- P/E8.2
- Dividend yield5.0%
- Financial periodQ1 2026
- RevenueEUR 2.02B
- Net incomeEUR 347.38M
- Free cash flowEUR 382.48M
- Gross margin60.0%
Valuation Snapshot
Bullrun's latest valuation model marks Hypera S.A. as 42.1% undervalued; latest market cap is EUR 2.55B; P/E is 8.2; dividend yield is 5.0%.
About Hypera S.A.
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands.
Frequently asked questions
Is Hypera S.A. overvalued or undervalued?
Bullrun's valuation model currently marks Hypera S.A. as 42.1% undervalued.
What is Hypera S.A.'s market cap?
Hypera S.A.'s market capitalization is EUR 2.55B.
What is Hypera S.A.'s P/E ratio?
Hypera S.A.'s price-to-earnings (P/E) ratio is 8.2.
Does Hypera S.A. pay a dividend?
Hypera S.A. has a dividend yield of 5.0%.
What does Hypera S.A. do?
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands;